Premium
In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs
Author(s) -
AbdelSalam Hassan A.
Publication year - 2005
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2005.01137.x
Subject(s) - miconazole , flucytosine , amphotericin b , nystatin , ketoconazole , fluconazole , itraconazole , cryptococcus neoformans , microbiology and biotechnology , broth microdilution , minimum inhibitory concentration , biology , pharmacology , antifungal , antibiotics
Summary The in vitro susceptibility of 29 clinical isolates of Cryptococcus neoformans to fluconazole, miconazole, itraconazole, ketoconazole, flucytosine, nystatin and amphotericin B was tested by broth and colorimetric microdilution methods. Most of the isolates showed uniform patterns of susceptibility to the used antifungal agents. Only three isolates exhibited resistance [fourfold or greater rise in the minimum inhibitory concentrations (MICs)] to the tested antifungal drugs. The MIC 50 and MIC 90 were 0.5–8 mg l −1 for 5‐flucytosine, 0.2–8.25 mg l −1 for nystatin, 0.5–16 mg l −1 for fluconazole and 0.2–12.5 mg l −1 for miconazole. However, MIC 50 and MIC 90 were in narrow range for the clinical yeast isolates in both methods used and showed 0.5–1 mg l −1 for amphotericin B and 0.016–0.25 mg l −1 for both ketoconazole and itraconazole. The combination of fluconazole plus flucytosine showed greater synergistic and fungicidal activity compared with that of fluconazole plus amphotericin B or the use of individual drugs.